These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Xanthogranulomatous Epithelial Tumors and Keratin-Positive Giant Cell Rich Tumors of Soft Tissue and Bone: Two Sides of the Same Coin. Folpe AL Surg Pathol Clin; 2024 Mar; 17(1):57-64. PubMed ID: 38278607 [TBL] [Abstract][Full Text] [Related]
7. Keratin-Positive Giant Cell-Rich Tumor: A Review and Update. Nishio J; Nakayama S; Koga K; Aoki M Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38792018 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility of CSF1 immunohistochemistry in tenosynovial giant cell tumor for differentiating from giant cell-rich tumors and tumor-like lesions of bone and soft tissue. Sugita S; Takenami T; Kido T; Aoyama T; Hosaka M; Segawa K; Sugawara T; Fujita H; Shimizu J; Murahashi Y; Emori M; Hasegawa T Diagn Pathol; 2022 Nov; 17(1):88. PubMed ID: 36320082 [TBL] [Abstract][Full Text] [Related]
9. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. West RB; Rubin BP; Miller MA; Subramanian S; Kaygusuz G; Montgomery K; Zhu S; Marinelli RJ; De Luca A; Downs-Kelly E; Goldblum JR; Corless CL; Brown PO; Gilks CB; Nielsen TO; Huntsman D; van de Rijn M Proc Natl Acad Sci U S A; 2006 Jan; 103(3):690-5. PubMed ID: 16407111 [TBL] [Abstract][Full Text] [Related]
10. Intramuscular Tenosynovial Giant Cell Tumor Harboring a Novel Mejbel H; Siegal GP; Wei S Int J Surg Pathol; 2022 May; 30(3):335-338. PubMed ID: 34657489 [TBL] [Abstract][Full Text] [Related]
11. Detection of CSF1 rearrangements deleting the 3' UTR in tenosynovial giant cell tumors. Ho J; Peters T; Dickson BC; Swanson D; Fernandez A; Frova-Seguin A; Valentin MA; Schramm U; Sultan M; Nielsen TO; Demicco EG Genes Chromosomes Cancer; 2020 Feb; 59(2):96-105. PubMed ID: 31469468 [TBL] [Abstract][Full Text] [Related]
12. Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee? Mastboom MJL; Hoek DM; Bovée JVMG; van de Sande MAJ; Szuhai K Histopathology; 2019 Jan; 74(2):332-340. PubMed ID: 30152874 [TBL] [Abstract][Full Text] [Related]
13. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Cupp JS; Miller MA; Montgomery KD; Nielsen TO; O'Connell JX; Huntsman D; van de Rijn M; Gilks CB; West RB Am J Surg Pathol; 2007 Jun; 31(6):970-6. PubMed ID: 17527089 [TBL] [Abstract][Full Text] [Related]
14. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. Tap WD; Wainberg ZA; Anthony SP; Ibrahim PN; Zhang C; Healey JH; Chmielowski B; Staddon AP; Cohn AL; Shapiro GI; Keedy VL; Singh AS; Puzanov I; Kwak EL; Wagner AJ; Von Hoff DD; Weiss GJ; Ramanathan RK; Zhang J; Habets G; Zhang Y; Burton EA; Visor G; Sanftner L; Severson P; Nguyen H; Kim MJ; Marimuthu A; Tsang G; Shellooe R; Gee C; West BL; Hirth P; Nolop K; van de Rijn M; Hsu HH; Peterfy C; Lin PS; Tong-Starksen S; Bollag G N Engl J Med; 2015 Jul; 373(5):428-37. PubMed ID: 26222558 [TBL] [Abstract][Full Text] [Related]
15. Giant Cell Tumors With HMGA2::NCOR2 Fusion : Clinicopathologic, Molecular, and Epigenetic Study of a Distinct Entity. Perret R; Malaka Z; Velasco V; Llamas-Gutierrez F; Ropars M; Linck PA; Hostein I; Azmani R; Valo I; Galmiche L; Moreau A; de Pinieux G; Michot A; Bochaton D; Coindre JM; Le Loarer F Am J Surg Pathol; 2023 Jul; 47(7):801-811. PubMed ID: 37170907 [TBL] [Abstract][Full Text] [Related]
16. Recurrent novel HMGA2-NCOR2 fusions characterize a subset of keratin-positive giant cell-rich soft tissue tumors. Agaimy A; Michal M; Stoehr R; Ferrazzi F; Fabian P; Michal M; Franchi A; Haller F; Folpe AL; Kösemehmetoğlu K Mod Pathol; 2021 Aug; 34(8):1507-1520. PubMed ID: 33742141 [TBL] [Abstract][Full Text] [Related]
17. A novel colony-stimulating factor 1 (CSF1) translocation involving human endogenous retroviral element in a tenosynovial giant cell tumor. Lipplaa A; Meijer D; van de Sande MAJ; Gelderblom H; Bovée JVMG; Mei H; Szuhai K Genes Chromosomes Cancer; 2023 Apr; 62(4):223-230. PubMed ID: 36504457 [TBL] [Abstract][Full Text] [Related]
19. Malignant Tenosynovial Giant Cell Tumor: The True "Synovial Sarcoma?" A Clinicopathologic, Immunohistochemical, and Molecular Cytogenetic Study of 10 Cases, Supporting Origin from Synoviocytes. Al-Ibraheemi A; Ahrens WA; Fritchie K; Dong J; Oliveira AM; Balzer B; Folpe AL Mod Pathol; 2019 Feb; 32(2):242-251. PubMed ID: 30206409 [TBL] [Abstract][Full Text] [Related]
20. Multimodal management of tenosynovial giant cell tumors (TGCT) in the landscape of new druggable targets. van der Heijden L; Spierenburg G; Kendal JK; Bernthal NM; van de Sande MAJ J Surg Oncol; 2023 Sep; 128(3):478-488. PubMed ID: 37537982 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]